Procizumab To Reduce Morbidity And Mortality In Circulatory Shock

Fact sheet
- Programme
- Horizon Europe & sub-programmes
- Companies
- EURICE
- Duration
- 42 months (June 2026 – November 2029)
- Project funding
- € 7,963,475.00
- Project partners
- 6
- Project website
- https://cure-shock.eu/
Project contact(s)
About the project
Circulatory shock caused by severe infection, major burns or traumatic injuries remains a major challenge in critical care, putting patients at high risk of organ failure and death. Despite medical advances, treatment remains largely supportive, highlighting the need for therapies that address the biological mechanisms driving shock.
CURE-SHOCK aims to close this gap by investigating a new targeted treatment approach for shock. At the centre of this ambition is Invobenitug, a novel monoclonal antibody developed by 4TEEN4 Pharmaceuticals that targets circulating DPP3 (cDPP3), a key driver of haemodynamic instability in severe shock.
In an international clinical trial across Germany, Poland and Ukraine, CURE-SHOCK will evaluate the safety and efficacy of Invobenitug in patients with septic, burn and traumatic shock. Rapid point-of-care testing at the patient’s bedside will identify those with elevated cDPP3 levels and help target treatment to patients who may benefit most. Through this biomarker-driven strategy, CURE-SHOCK aims to advance precision medicine in circulatory shock and ultimately improve treatment for critically ill patients.